Previous 10 | Next 10 |
In RATIONALE 309, tislelizumab in combination with chemotherapy significantly prolonged progression-free survival for patients, with survival benefit observed across patient subgroups The safety profile of the combination was consistent with known risks of each treatment agent...
Zymeworks (NYSE:ZYME) partner BeiGene (NASDAQ:BGNE) has dosed the first patient in a phase 3 trial evaluating the latter's zanidatamab for advanced or metastatic HER2-positive gastroesophageal adenocarcinomas. Zymeworks is receiving an $8M milestone payment from BeiGene as a result of a colla...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...
Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...
Beijing's BeiGene announced its Shanghai STAR Exchange IPO will raise $3.5 billion in gross proceeds for the company, more than the predictions of $3 billion. Suzhou Abogen Biosciences, an mRNA company, raised $300 million to support development of its COVID-19 vaccine and other drug ...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has approved SYLVANT ® (siltuximab for injection) for the treatment of adult patients with multicentric Castleman disease (MCD) wh...
BeiGene (NASDAQ:BGNE; HKEX:06160), a global science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that three of its medicines have been added to the most recent Nati...
Results from RATIONALE 309 trial of tislelizumab in combination with chemotherapy in nasopharyngeal cancer will be presented in a proffered paper Accepted abstracts also include new findings from clinical studies of tislelizumab and sitravatinib BeiGene (NASDAQ: ...
BeiGene (NASDAQ:BGNE) has priced its previously announced initial public offering of shares on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE) at RMB192.60 per ordinary share. It indicates HK$234.89 per ordinary share and $391.68 per American Dep...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the pricing of its previously announced initial public off...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...